Therapeutic Solutions International Inc (TSOI)

[BigBadWolf]

F-13 F-14 https://www.otcmarkets.com/filing/html?id=16210798&guid=xrG-kWHM7TC6dth
Any company needs to entice new investors to absorb when a company's survival rest on selling/using discounted shares in lieu of any real cash/revenues. When not the SP declines, FACT! Here's to hope of an expedited learning curve after the last decade plus of said.
Note 9 – Equity

Our authorized capital stock consists of an aggregate of 3,505,000,000 shares, comprised of 3,500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of September 30, 2022, we have 2,588,063,537 shares of common stock and 2 shares preferred shares issued and outstanding.

In 2021, we issued 4,850,075 shares of common stock for an investment in the Company’s Private Placement of $285,500.

In 2021, we issued 21,000,000 shares of common stock, valued at $858,900 for consulting services.

In 2021, we issued 8,341,723 shares of common stock, valued at $239,799 for salaries.

In 2021, we issued 1,500,000 shares of common stock, valued at $58,900 for land development.

In 2021, we issued 21,690,671 shares of common stock for the conversion of convertible notes of $1,019,014.

In 2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.

In 2022, we issued 25,302,577 shares of common stock, valued at $508,078 for consulting services. Conversion price 02

In 2022, we issued 1,034,482 shares of common stock, valued at $29,999 for salaries.

In 2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for a license.

In 2022, we issued 41,700,228 shares of common stock for the conversion of convertible notes of $595,042.

In 2022, we issued 11,000,000 shares of common stock, valued at $242,320 for prepaid fees.

In 2022, we issued 4,000,000 shares of common stock, valued at $50,400 for land development.

On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.

On August 9, 2022, we issued 2 shares of preferred shares, valued at 0.001 per share.

F-13

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2022

Note 10 – Subsequent events

On October 5, 2022, we issued 110,000 shares of common stock, valued at .0122 per share, for consulting services.

On October 7, 2022, we issued 5,322,581 shares of common stock for the partial conversion of $33,000 for convertible note dated April 6, 2022.

On October 11, 2022, we issued 8,014,113 shares of common stock for the complete conversion of $49,687.50 for convertible note dated April 6, 2022.

On November 2, 2022, we issued 3,000,000 shares of common stock, valued at .0099 per share, for consulting services.

On November 2, 2022, we issued 3,777,777 shares of common stock, valued at .0099 per share, for salaries.

In accordance with ASC 855, the Company has analyzed its operations subsequent to November 17, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Note 11 – Commitments and Contingencies

Effective March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2023.

Total rent expense for the nine months is $18,783.

The lease will expire in 2023. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company). Maturities of Leases were:

Future minimum lease payments as of December 31, 2022, are as follows:

For the year ending December 31,

2022 $ 6,249
2023 $ 8,612

As of March 25, 2022, we entered into an asset transfer and license agreement, which will be amortized over the life of the agreement. The agreement is for five years. The Company has made an initial payment of $200,000. Within six months, the Company will make a second payment of $1.8 million. The Company has not made the payment yet. This has not affected the agreement.
F-14
https://www.otcmarkets.com/filing/html?id=16210798&guid=xrG-kWHM7TC6dth